The PCPT biorepository and extended data was used to further explore the initial suggestion that some men taking finasteride were at risk of developing high-grade prostate cancers, and to look at the value of prostate-specific antigen (PSA) for early detection. Researchers showed that:
- Finasteride improves the biopsy detection of prostate cancers (by reducing gland volume) and increases the sensitivity of PSA for detecting prostate cancer, in general, and high-grade cancer, in particular;
- Men taking finasteride may not have increased risk of high-grade prostate cancer;
- Finasteride prevents cancer for which treatment would be recommended;
- Finasteride decreases risk of high-grade prostatic intraepithelial neoplasia (PIN), which may be a precursor to prostate cancer; and
- Prostate cancer, including high-grade cancer, can be present even when PSA levels are 4.0 ng/ml or less.
An extensive investigator-initiated program project grant includes studies to evaluate androgen metabolism; diet and diet-related factors; insulin-like growth factor axis and insulin resistance; genotypic and phenotypic studies of inflammation; and oxidative damage and DNA repair.
or
The PCPT biorepository and extended data also was used in an extensive investigator-initiated program project grant that includes studies to evaluate androgen metabolism; diet and diet-related factors; insulin-like growth factor axis and insulin resistance; genotypic and phenotypic studies of inflammation; and oxidative damage and DNA repair.
References
Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep;99(18):1366-74. Epub 2007 Sep 11.
[ PubMed Abstract ]
Hoque A, Abrosone CB, Till C, et al. Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2010 Apr;3(4):478-83. Epub2010 March 23.
[ PubMed Abstract ]
Kaplan SA, Roehrborn CG, Meehan AG, et al.: PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology. 2009 73(5):935-9. Epub 2009 Mar 28.
[ PubMed Abstract ]
Kristal AR, Schenk JM, Song Y, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 168 (12): 1416-24, 2008. Epub 2008 Oct 21.
[ PubMed Abstract ]
Lucia MS, Darke AK, Goodman PJ, et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res. 2008 1(3):167-73. Epub 2008 May 18.
[ PubMed Abstract ]
Lucia MS, Epstein JI, Goodman PJ, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.
[ PubMed Abstract ]
McKinney MM, Weiner BJ, Wang V. Recruiting participants to cancer prevention clinical trials: lessons from successful community oncology networks. Oncol Nurs Forum. 2006 Sep 1;33(5):951-9.
[ PubMed Abstract ]
Pinsky P, Parnes H, Ford L. Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer Prev Res. 2008 1(3):182-6. Epub 2008 May 18.
[ PubMed Abstract ]
Price DK, Chau CH, Till C, et al. Androgen receptor CAG repeat length and association with prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Urol. 2010 Dec:184(6):2297-302. Epub 2010 Oct 16.
[ PubMed Abstract ]
Redman M, Tangen C, Goodman P, et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res. 2008 1 (3):174-81. Epub 2008 May 18
[ PubMed Abstract ]
Tang L, Yao S. Til C, et al. Repeat polymorphisms in estrogenmetabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogensis. 2011 Oct: 32 (10):1500-6. Epub 2011 Jul 18.
[ PubMed Abstract ]
Thompson IM, Ankerst DP, Chi C,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006 Apr 19;98(8):529-34.
[ PubMed Abstract ]
Thompson IM, Pauler Ankerst D, Chi C, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20;25(21):3076-81.
[ PubMed Abstract ]
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med. 2004 May27; 350(22):2239-46.
[ PubMed Abstract ]
Yao S, Til C, Kristal AR, et al. Serum estrogen levels and prostate cancer risk in the Prostate Cancer Prevention Trial: a nested case-control study. Cancer Causes Control. 2011 Aug:22(8):1121-31. Epub 2011 Jun 11.
[ PubMed Abstract ]